Porcine rotavirus VP4 truncated protein and its expression and application in preventing and treating porcine diarrhea
By introducing proline and histidine mutations into the swine rotavirus VP4 truncated protein, it improves its stability and immunogenicity, and the shortcomings of the existing VP4 truncated protein in inducing immune effects are solved, achieving more effective prevention and treatment effects.
CN119119212BActive Publication Date: 2025-05-16JIANGSU SANYI ANIMAL NUTRITION TECH +3
2 Cites 0 Cited by
Patent Information
- Application Number
- CN202411296852.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-18
- Publication Date
- 2025-05-16
- Estimated Expiration
- 2044-09-18
AI Technical Summary
Technical Problem
The existing pig rotavirus VP4 truncated protein has insufficient immunity in inducing immune effects and cannot effectively protect or treat pig diarrhea.
Method used
The stability of VP4 truncated protein is enhanced by introducing proline and histidine mutations, thereby enhancing its immunogenicity.
Benefits of technology
The immune performance of VP4 truncated protein has been improved, making it a more effective vaccine and drug development material, which can better prevent and treat swine rotavirus infection.
✦ Generated by Eureka AI based on patent content.
Abstract
The present application provides a truncated protein of porcine rotavirus VP4 and its expression and application in preventing and treating porcine diarrhea; the amino acid sequence of the truncated protein of porcine rotavirus VP4 of the present application is SEQ ID NO.3, which has improved immunogenicity by appropriately truncating the nitrogen-terminal part of VP4 and introducing histidine and proline mutations; and can be used to prepare injectable / oral vaccines or drugs.
Need to check novelty before this filing date? Find Prior Art